Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:46:29.989Z.
Consensus retrieved: 2026-10-06T10:54:54.950Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:46:29.989Z.
Quote observation: 2026-10-06T14:45:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d6bd3278d76725a85d4cb05495e45b99d0fd89b23371e3701c8289362793e8f
Forward PE Ratio (N/A) = Dated Quote Price ($12.00) / Consensus Forward EPS ($-1.32)
FORWARD PE RATIO
N/A
Design Therapeutics, Inc.
Market Cap
$749.48M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $749.48M | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $750.01M | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $743.33M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $764.02M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $766.63M | N/A |
| Geron Corporation (GERN)vs › | $769.83M | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $723.04M | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $722.55M | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $717.21M | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $784.88M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $12.00, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.32 | $-1.52 – $-1.15 | 6 | n/m |
| 2027-12-31 | $-1.59 | $-1.99 – $-1.14 | 6 | n/m |
| 2028-12-31 | $-1.95 | $-2.31 – $-1.49 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
